Comparing the current results to its competitors, Endo International Plc reported Revenue decrease in the 4 quarter 2023 year on year by -10.45 %, faster than the overall decrease of Endo International Plc's competitors by -9.29 %, recorded in the same quarter.
Endo International Plc, slower than the average decrease reported by the company's competitors of -93.62 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -93.62 %
Endo International Plc's Comment on Competition and Industry Peers
The company develops proprietary products, technologies, and intellectual property to establish a competitive position, while acknowledging no guarantee of protection from competition. Its generic products, primarily marketed through the Sterile Injectables and Generic Pharmaceuticals segments, focus on high-barrier-to-entry items, particularly complex sterile injectables and first-to-file or first-to-market opportunities. First-to-market products are used to reduce risks associated with competitive pressures. The company operates manufacturing facilities in the U.S. and India and employs an integrated, team-based product development approach. Its product portfolio includes branded Specialty Products and Established Products, with an emphasis on products facing limited generic competition to maintain market share and profitability. The company prioritizes injectable products that involve scientific, regulatory, legal, and technical complexities and regularly reviews development projects to optimize investment returns. Competitors identified in company filings include Endo International plc.
January 22, 2024
Endo s Paladin Labs Launches XCOPRI in Canada, Providing New Treatment Option for Adults with Partial-Onset SeizuresMONTREAL, Jan. 22, 2024 - Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), made a groundbreaking announcement today, revealing the availability of XCOPRI (cenobamate tablets) in Canada. Designed as an adjunctive therapy, XCOPRI provides adults with an innovative treatment option for managing partial-onset seizures.Partial-onset seizures, also known as focal seizures, are a common form of epilepsy that begins in a specific part of the brain. These seizures can cause a wide range of symptoms, including sensory changes, involuntary movements, altered consciousness, or other ...
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
Biophytis SA is a biotechnology company that focuses on developing innovative therapeutics for age-related diseases, with a specific emphasis on degenerative eye diseases and muscle wasting conditions. They leverage their expertise in biology and clinical development to discover and advance targeted drug candidates, aiming to address the unmet medical needs of patients in these areas.
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
Amneal Pharmaceuticals Inc operates as a fully integrated pharmaceutical company, primarily focused on the development, manufacturing, and distribution of generic and specialty pharmaceutical products. Their business model revolves around identifying market opportunities, conducting research to develop cost-effective formulations, and leveraging their expansive manufacturing capabilities to produce and distribute a wide range of pharmaceuticals to customers globally. Additionally, they aim to provide high-quality products at competitive prices while continuously investing in research and development to expand their product portfolio.
Sources:
Endo International Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Endo International Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
